News
AgNovos Bioscience Announces 150th Patient Enrolled in RESTORE
AgNovos Bioscience announces that more than 150 patients have been enrolled in the RESTORE randomized, controlled trial of AGN1 LOEP.
News & Events
Keep up to date on AgNovos events and related news
Featured posts
All Articles
AgNovos Healthcare to Co-sponsor ESCEO-AgNovos Young Investigator Awards at World Congress on Osteoporosis
AgNovos will once again co-sponsor the ESCEO-AgNovos Young Investigator Awards at this year’s virtual World Congress on Osteoporosis from August 26-29th.
AgNovos Healthcare to Participate in World Congress on Osteoporosis
AgNovos Healthcare will participate in this year’s virtual World Congress on Osteoporosis from August 26-29.
AGN1 LOEP SV Kit Receives an Investigational Device Exemption (IDE) from the U.S. FDA
AgNovos Healthcare, a developer of medical technology products leveraging regenerative medicine to treat the local effects of bone disease, announced today that its newest investigational product, AGN1 Local Osteo-enhancement Procedure (LOEP) Small Volume (SV) kit has received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration.
AgNovos Healthcare participates at virtual congress digital O&U 2020 on October 19th – 23rd
AgNovos Healthcare will participate at the virtual congress digital O&U 2020
AgNovos Healthcare has generated strong interest with the Breakthrough Designation by the FDA and was mentioned in reputable press portals
The recently issued press release on the FDA's "Breakthrough Designation" for AgNovos' newest investigational product, AGN1 Local Osteo-enhancement Procedure (LOEP) Small Volume (SV) Kit, has generated a strong of interest in the industry and has been posted on several reputable press portals.
AgNovos Healthcare Receives Breakthrough Designation for Spine Device
AgNovos Healthcare is pleased to announce that its newest investigational product, AGN1 Local Osteo-enhancement Procedure (LOEP) Small Volume (SV) Kit, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).